NSE · MEDICAMEQ · Healthcare
Medicamen Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,17,34,23,000 Cr with net profit ₹12,25,89,000 Cr — a 10.45% net margin, versus 9.96% the period before.
Shareholding
As of 2026-06-30
- Promoter62.97%
- Public37.03%
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 2.11× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
AI analysis
AI-generated · google/gemini-2.5-flashMedicamen Biotech Ltd., operating in the Pharmaceuticals sector, has a market capitalization of Rs 335 Cr. The company reported a profit margin of 5.5% and a dividend yield of 40%. The debt-to-equity ratio stands at 0.15.
Positives
- +The company has a high dividend yield of 40%.
- +The return on equity (ROE) is significantly high at 349.89%.
- +The debt-to-equity ratio is low at 0.15.
- +There is no promoter share pledge recorded.
Negatives
- −Revenue growth for the full year was negative at -9.35%.
- −The company is currently under LT-ASM, indicating regulatory surveillance.
- −The Return on Capital Employed (ROCE) is relatively low at 4.7882%.
- −Promoter holding decreased from 40.4569% in the current period to 34.7% in Mar 2017.
- −No annual revenue or profit figures were provided for the most recent financial year.
Financial Performance
The company’s revenue growth was -9.35%. Quarterly revenue in March 2026 was Rs 60.65 Cr with a net profit of Rs 3.86 Cr. In December 2025, revenue was Rs 46.91 Cr with a net profit of Rs 2.19 Cr. Net profit in March 2025 was Rs 2.42 Cr on revenue of Rs 29.61 Cr.
Profitability & Returns
Medicamen Biotech Ltd. has a profit margin of 5.5%. The return on equity (ROE) is 349.89%, while the return on capital employed (ROCE) is 4.7882%. The earnings per share (EPS) is Rs 7.11.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.15. The book value per share is Rs 203.17. No figures for total assets or liabilities were provided.
Ownership & Pledges
As of June 30, 2026, promoter holding was 40.4569%. Public shareholding was 59.069%, with DIIs holding 0.4032% and FIIs holding 0.0709%. Total institutional holding was 0.4741%. There is no promoter share pledge recorded.
Regulatory & Surveillance
Medicamen Biotech Ltd. is currently under LT-ASM (Long Term Additional Surveillance Measure) · ASM 1, which indicates increased regulatory monitoring.
Data as of — price: 2026-07-30 · financials: Mar 20 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.